Impact of AI on the regulation of medical products: Implementing the AI White Paper principles
Impact of AI on the regulation of medical products Implementing the AI White Paper principles
This publication outlines the Medicines and Healthcare products Regulatory Agency's (MHRA) response to the UK government's AI White Paper and its five core principles. It details the agency's approach across three perspectives: as a regulator of AI medical products undergoing regulatory reform, as a public service organization optimizing its internal operations using AI, and as an evidence-based decision-maker evaluating third-party AI-generated data. The report highlights ongoing and planned guidance, international collaboration, regulatory sandboxes like AI-Airlock, and allocated resources.
Summary and content fields are drawn from the document text and are pending editorial review.
Who issued it
Who it governs
Medical device manufacturers, software developers, healthcare providers, and researchers looking to understand how the MHRA regulates AI in healthcare and applies the UK AI White Paper principles.
What the document contains
The document covers the MHRA's strategy for regulating AI-enabled medical devices, reforming medical device regulations, utilizing AI internally to streamline regulatory workflows, and managing evidence supplied by third parties in clinical and real-world contexts.
Detailed binding legal text for upcoming post-2024 regulations and specific technical compliance thresholds are not fully detailed, as many reforms and guidance documents are noted as planned for future publication.
- The MHRA has adopted the five key principles of the UK AI White Paper (safety, transparency, fairness, accountability, and contestability) across its regulatory functions.
- Medical software and AI products intended for medical purposes fall under the UK Medical Devices Regulations 2002 and are subject to upcoming regulatory reforms and up-classification.
- The MHRA is launching the AI-Airlock, a regulatory sandbox for AI as a Medical Device (AIaMD), in spring 2024.
- The agency is exploring internal uses of supervised machine learning, Large Language Models, and generative AI to improve regulatory service efficiency and document assessment.
- International collaboration with bodies like the IMDRF, US FDA, and Health Canada is central to aligning standards and developing guidance such as Predetermined Change Control Plans.
· Introduction · The Pro-innovation approach to the regulation of AI · Part 1 – The MHRA as a regulator of AI products · Part 2 – The MHRA as a public service organisation delivering time-critical decisions · Part 3 – The MHRA as an organisation that makes evidence-based decisions that impact on public and patient safety, where that evidence is often supplied by third parties · Conclusion
How it scores
Each score is backed by a quote verified against the document text. Editorial review has not yet confirmed them.
Accountability
4/5Clear responsibility for AI outcomes
The regulations include clear responsibilities and accountabilities for manufacturers of medical devices, the MHRA and conformity assessment bodies.
Part 1 – Current Regulations
screening score · 2026-10-23
Fairness
3/5Non-discrimination and equitable treatment
As Dame Margaret Whitehead notes, the advance of AI brings with it not only great potential benefits to society but also possible harm through inherent bias against certain groups in the population, notably women, ethnic minorities and disadvantaged socio-economic groups.
Part 1 – Principle 3 of the AI White Paper addresses fairness
screening score · 2026-10-23
Human Dignity
0/5Respect for the inherent worth of persons
screening score · 2026-10-23
Human Oversight
3/5Humans remain in control of consequential decisions
This application would reduce the need for human involvement in these early assessment stages, enabling human expertise to be better targeted to make the critical assessment of whether the benefits of the product outweigh the risks.
Part 2 – Improving the quality of applications for medicines licences
screening score · 2026-10-23
Privacy
2/5Protection of personal data and private life
Security, including cyber security, is central to how we operate as an organisation that holds patient and commercial data.
Part 2 – Approach to expanding and optimising AI
screening score · 2026-10-23
Transparency
3/5Openness about how AI systems work and are used
Current regulations set requirements for usability, labelling and the information manufacturers must supply for intended users. This should include how the device works.
Part 1 – Principle 2 of the AI White Paper considers transparency and explainability
screening score · 2026-10-23
Enforcement
4/5Consequences and compliance mechanisms with real force
This will allow us to investigate, and where appropriate take enforcement action, and update our list of unsafe websites for the public to check against.
Part 2 – Protecting consumers from fraudulent medical products
screening score · 2026-10-23
Impact Assessment
4/5Required assessment of an AI system's risks/impacts before or during use
These regulations cover the lifecycle of the product from clinical investigation pre-market, through assessing conformity with regulations, registering the product with the MHRA and placing it on the market.
Part 1 – Current Regulations
screening score · 2026-10-23